Perrigo (PRGO +1.6%
) files an Abbreviated New Drug Application
with the FDA for albuterol sulfate HFA inhalation aerosol, a generic version of Teva Pharmaceutical's (TEVA +1%
) ProAir HFA. The filing involves contributions from both PRGO
and Catalent Pharma Solutions, who partnered on the development. TEVA
claims the application violates its patent on the drug, and yesterday it filed suit against both companies in U.S. District Court alleging patent infringement.